Patrick W. Smith Purchases 5,669 Shares of OncoCyte Co. (NASDAQ:OCX) Stock

OncoCyte Co. (NASDAQ:OCX) major shareholder Patrick W. Smith acquired 5,669 shares of the company’s stock in a transaction on Monday, January 13th. The stock was acquired at an average price of $2.08 per share, with a total value of $11,791.52. Following the acquisition, the insider now owns 1,779,572 shares in the company, valued at approximately $3,701,509.76. This trade represents a 0.32 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

OncoCyte Stock Performance

Shares of OCX opened at $2.08 on Friday. The firm’s 50-day simple moving average is $2.39 and its two-hundred day simple moving average is $2.84. OncoCyte Co. has a fifty-two week low of $1.97 and a fifty-two week high of $3.49.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The company had revenue of $0.12 million for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same period in the previous year, the business posted ($0.57) earnings per share. As a group, equities analysts expect that OncoCyte Co. will post -2.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OncoCyte

An institutional investor recently raised its position in OncoCyte stock. FNY Investment Advisers LLC increased its holdings in shares of OncoCyte Co. (NASDAQ:OCX) by 15.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 49,377 shares of the company’s stock after purchasing an additional 6,481 shares during the quarter. FNY Investment Advisers LLC owned 0.29% of OncoCyte worth $117,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 55.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research note on Wednesday, November 13th. StockNews.com assumed coverage on OncoCyte in a research report on Monday, January 13th. They issued a “sell” rating for the company.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.